Elevated Levels of the Anti-Inflammatory Interleukin-1 Receptor Antagonist Precede the Onset of Type 2 Diabetes: The Whitehall II Study

OBJECTIVE—Interleukin-1 receptor antagonist (IL-1Ra), a natural inhibitor of interleukin-1β, has been shown to improve β-cell function and glycemic control in patients with type 2 diabetes. The aim of this study was to investigate whether baseline systemic levels of IL-1Ra are associated with incide...

Descripción completa

Detalles Bibliográficos
Autores principales: Herder, Christian, Brunner, Eric J., Rathmann, Wolfgang, Strassburger, Klaus, Tabák, Adam G., Schloot, Nanette C., Witte, Daniel R.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2009
Materias:
Epidemiology/Health Services Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646020/
https://www.ncbi.nlm.nih.gov/pubmed/19073760
http://dx.doi.org/10.2337/dc08-1161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646020/
https://www.ncbi.nlm.nih.gov/pubmed/19073760
http://dx.doi.org/10.2337/dc08-1161

Ejemplares similares